Biocryst Pharmaceuticals Inc (BCRX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biocryst Pharmaceuticals Inc (BCRX)

BCRX 6.765

-1.5%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: IRWIN JAMES FRANKEL	1/25/2008 8:52:44 AM
	of 269

BCRX BioCryst Pharm: Delay in Phase III; tgt cut to $4.50 - Caris (4.89 ) Caris cuts their tgt on BCRX to $4.50 from $8, given the delay in the pivotal Phase III peramivir trial for influenza. BioCryst (BCRX) has three small molecule drugs in Phase II; lead agent peramivir for influenza, BCX-4208 for psoriasis, and Fodosine for cutaneous T-cell lymphoma (C.T.C.L.).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next